Pharmalittle: We’re reading about the end of a Lilly drug shortage, a Novo obesity trial disappointment, and more
Novo Nordisk’s next-generation obesity candidate led to substantial weight loss in a pivotal study but fell short of expectations
Related Articles
Advancing Female Bladder Cancer Care: Insights from AUA’s First Specialized Course – Armine Smith
Ashish Kamat introduces Armine Smith to discuss the intricacies of treating female bladder cancer, emphasizing organ and sexual function preservation during radical cystectomy. Highlighting a…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression – Neil Fleshner
Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance…
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.
A bad day to be a salmon
Today’s health news includes the FDA’s update to its definition of “healthy” foods, the maternal mortality data debate, and more.
Ionis wins FDA approval for a rare disease therapy that lowers triglycerides
Ionis won FDA approval for a drug for patients with a deadly genetic disease that impedes the body’s ability to break down fats
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Ionis wins FDA approval for a rare disease therapy that lowers triglycerides
Ionis won FDA approval for a drug for patients with a deadly genetic disease that impedes the body’s ability to break down fats
Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer – Daniel Kwon
Daniel Kwon presents a study on genetic counseling for Veterans with advanced prostate cancer. This mixed-methods research combines in-depth qualitative interviews and quantitative surveys to…